Page 2 of 2
12

2023

Thompson CM, Kirman C, Harris MA. 2023. Derivation of oral cancer slope factors for hexavalent chromium informed by pharmacokinetic models and in vivo genotoxicity data. Regul Toxicol Pharmacol 145(Dec):105521; doi: 10.1016/j.yrtph.2023.105521. PMID: 37863416.

View Abstract

Wikoff D, Thompson C, Vincent M, Fitch S, Britt J, Reichert H, Rogers S. 2023. Protocol for the systematic review of formaldehyde and lymphohematopoietic (LHP) cancers. OSF | Protocol_Formaldehyde and LHP SR.pdf.

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

View Abstract

2021

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.

View Abstract

2018

Borghoff S, Wikoff D, Urban JD, Rager JE. A systematic approach to identify plausible mode-of-actions (MOA) for an increased incidence of lung tumors in mice with chronic exposure to 4-methylimidazole (4-MEI). Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

View Abstract

Proctor DM, Suh M, Chappell G, Borghoff SJ, Thompson CM, Wiench K, Finch L, Ellis-Hutchings R. 2018. An adverse outcome pathway (AOP) for forestomach tumors induced by non-genotoxic initiating events. Regul Toxicol Pharmacol, 96(July):30-40; doi: 10.1016/j.yrtph.2018.04.016.

View Abstract

2014

Wikoff D, Thompson C, Perry C, White M, Fitzgerald L, Borghoff S, Haws LC. Development of an oral cancer slope factor and lifetime average daily dose estimates for TBBPA. Presented at the Society of Toxicology’s 53rd Annual Meeting, Phoenix, AZ, March 2014.

View Abstract

2013

Proctor DM, Suh M, Thompson CM, Harris MA. Mode of action evaluation for hexavalent chromium-induced lung cancer. Presented at Society of Toxicology 52nd Annual Meeting, San Antonio, TX, March 2013.

View Abstract

2011

Haws L, Proctor D, Thompson C, Harris M. Research plan to fill data gaps in the mode of action for cancer risk assessment of hexavalent chromium in drinking water. Presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

View Abstract

2010

Gatto NM, Kelsh MA, Mai DH, Suh M, Proctor DM. 2010. Occupational exposure to hexavalent chromium and cancers of the gastrointestinal tract: A meta-analysis. Cancer Epidemiol 34(4):388-99.

View Abstract
Page 2 of 2
12